立体定向分次放疗联合全脑放射治疗脑转移瘤疗效分析

Objective To evaluate efficiency of brain metastases tumor using X-knife under farctionational stereotactie radiotherapy (FSRT) combine with whole brain radiotherapy (WBRT). Methods Retrospective comparing 51 patients treated by FSRT plus WBRT (FSRT + WBRT group) with 35 patients treated by WBRT alone (WBRT group) on the effecting rate and survival rate. Results The completeness response rate was 49 % and 26 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. The effecting rate was 80 % and 71 % (P 0.05) in FSRT + WBRT and WBRT groups, respectively. The middle survival time was (11.0 ± 1.5) months and (6.5 ± 0.5) months (P < 0.05) in FSRT + WBRT and WBRT groups, respeetivley. The 0.5-, 1.0- and 1.5-years survival rate was 63 % and 41 % (P 0.05), 51 % and 23 % (P 0.05) and 24 % and 9 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. Conclusions The method with FSRT plus WBRT in the treatment of brain metastases tumor is safe and relieved focal symptom of patients quickly with lesser injury on normal tissue and the survival time be prolonged, it has better therapeutic effects than WBRT alone for treating brain metastases tumor.     

立体定向分次放疗联合全脑放射治疗脑转移瘤疗效分析

Objective To evaluate efficiency of brain metastases tumor using X-knife under farctionational stereotactie radiotherapy (FSRT) combine with whole brain radiotherapy (WBRT). Methods Retrospective comparing 51 patients treated by FSRT plus WBRT (FSRT + WBRT group) with 35 patients treated by WBRT alone (WBRT group) on the effecting rate and survival rate. Results The completeness response rate was 49 % and 26 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. The effecting rate was 80 % and 71 % (P 0.05) in FSRT + WBRT and WBRT groups, respectively. The middle survival time was (11.0 ± 1.5) months and (6.5 ± 0.5) months (P < 0.05) in FSRT + WBRT and WBRT groups, respeetivley. The 0.5-, 1.0- and 1.5-years survival rate was 63 % and 41 % (P 0.05), 51 % and 23 % (P 0.05) and 24 % and 9 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. Conclusions The method with FSRT plus WBRT in the treatment of brain metastases tumor is safe and relieved focal symptom of patients quickly with lesser injury on normal tissue and the survival time be prolonged, it has better therapeutic effects than WBRT alone for treating brain metastases tumor.     

立体定向分次放疗联合全脑放射治疗脑转移瘤疗效分析

Objective To evaluate efficiency of brain metastases tumor using X-knife under farctionational stereotactie radiotherapy (FSRT) combine with whole brain radiotherapy (WBRT). Methods Retrospective comparing 51 patients treated by FSRT plus WBRT (FSRT + WBRT group) with 35 patients treated by WBRT alone (WBRT group) on the effecting rate and survival rate. Results The completeness response rate was 49 % and 26 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. The effecting rate was 80 % and 71 % (P 0.05) in FSRT + WBRT and WBRT groups, respectively. The middle survival time was (11.0 ± 1.5) months and (6.5 ± 0.5) months (P < 0.05) in FSRT + WBRT and WBRT groups, respeetivley. The 0.5-, 1.0- and 1.5-years survival rate was 63 % and 41 % (P 0.05), 51 % and 23 % (P 0.05) and 24 % and 9 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. Conclusions The method with FSRT plus WBRT in the treatment of brain metastases tumor is safe and relieved focal symptom of patients quickly with lesser injury on normal tissue and the survival time be prolonged, it has better therapeutic effects than WBRT alone for treating brain metastases tumor.     

立体定向分次放疗联合全脑放射治疗脑转移瘤疗效分析

Objective To evaluate efficiency of brain metastases tumor using X-knife under farctionational stereotactie radiotherapy (FSRT) combine with whole brain radiotherapy (WBRT). Methods Retrospective comparing 51 patients treated by FSRT plus WBRT (FSRT + WBRT group) with 35 patients treated by WBRT alone (WBRT group) on the effecting rate and survival rate. Results The completeness response rate was 49 % and 26 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. The effecting rate was 80 % and 71 % (P 0.05) in FSRT + WBRT and WBRT groups, respectively. The middle survival time was (11.0 ± 1.5) months and (6.5 ± 0.5) months (P < 0.05) in FSRT + WBRT and WBRT groups, respeetivley. The 0.5-, 1.0- and 1.5-years survival rate was 63 % and 41 % (P 0.05), 51 % and 23 % (P 0.05) and 24 % and 9 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. Conclusions The method with FSRT plus WBRT in the treatment of brain metastases tumor is safe and relieved focal symptom of patients quickly with lesser injury on normal tissue and the survival time be prolonged, it has better therapeutic effects than WBRT alone for treating brain metastases tumor.     

立体定向分次放疗联合全脑放射治疗脑转移瘤疗效分析

Objective To evaluate efficiency of brain metastases tumor using X-knife under farctionational stereotactie radiotherapy (FSRT) combine with whole brain radiotherapy (WBRT). Methods Retrospective comparing 51 patients treated by FSRT plus WBRT (FSRT + WBRT group) with 35 patients treated by WBRT alone (WBRT group) on the effecting rate and survival rate. Results The completeness response rate was 49 % and 26 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. The effecting rate was 80 % and 71 % (P 0.05) in FSRT + WBRT and WBRT groups, respectively. The middle survival time was (11.0 ± 1.5) months and (6.5 ± 0.5) months (P < 0.05) in FSRT + WBRT and WBRT groups, respeetivley. The 0.5-, 1.0- and 1.5-years survival rate was 63 % and 41 % (P 0.05), 51 % and 23 % (P 0.05) and 24 % and 9 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. Conclusions The method with FSRT plus WBRT in the treatment of brain metastases tumor is safe and relieved focal symptom of patients quickly with lesser injury on normal tissue and the survival time be prolonged, it has better therapeutic effects than WBRT alone for treating brain metastases tumor.     

立体定向分次放疗联合全脑放射治疗脑转移瘤疗效分析

Objective To evaluate efficiency of brain metastases tumor using X-knife under farctionational stereotactie radiotherapy (FSRT) combine with whole brain radiotherapy (WBRT). Methods Retrospective comparing 51 patients treated by FSRT plus WBRT (FSRT + WBRT group) with 35 patients treated by WBRT alone (WBRT group) on the effecting rate and survival rate. Results The completeness response rate was 49 % and 26 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. The effecting rate was 80 % and 71 % (P 0.05) in FSRT + WBRT and WBRT groups, respectively. The middle survival time was (11.0 ± 1.5) months and (6.5 ± 0.5) months (P < 0.05) in FSRT + WBRT and WBRT groups, respeetivley. The 0.5-, 1.0- and 1.5-years survival rate was 63 % and 41 % (P 0.05), 51 % and 23 % (P 0.05) and 24 % and 9 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. Conclusions The method with FSRT plus WBRT in the treatment of brain metastases tumor is safe and relieved focal symptom of patients quickly with lesser injury on normal tissue and the survival time be prolonged, it has better therapeutic effects than WBRT alone for treating brain metastases tumor.     

立体定向分次放疗联合全脑放射治疗脑转移瘤疗效分析

Objective To evaluate efficiency of brain metastases tumor using X-knife under farctionational stereotactie radiotherapy (FSRT) combine with whole brain radiotherapy (WBRT). Methods Retrospective comparing 51 patients treated by FSRT plus WBRT (FSRT + WBRT group) with 35 patients treated by WBRT alone (WBRT group) on the effecting rate and survival rate. Results The completeness response rate was 49 % and 26 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. The effecting rate was 80 % and 71 % (P 0.05) in FSRT + WBRT and WBRT groups, respectively. The middle survival time was (11.0 ± 1.5) months and (6.5 ± 0.5) months (P < 0.05) in FSRT + WBRT and WBRT groups, respeetivley. The 0.5-, 1.0- and 1.5-years survival rate was 63 % and 41 % (P 0.05), 51 % and 23 % (P 0.05) and 24 % and 9 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. Conclusions The method with FSRT plus WBRT in the treatment of brain metastases tumor is safe and relieved focal symptom of patients quickly with lesser injury on normal tissue and the survival time be prolonged, it has better therapeutic effects than WBRT alone for treating brain metastases tumor.     

立体定向分次放疗联合全脑放射治疗脑转移瘤疗效分析

Objective To evaluate efficiency of brain metastases tumor using X-knife under farctionational stereotactie radiotherapy (FSRT) combine with whole brain radiotherapy (WBRT). Methods Retrospective comparing 51 patients treated by FSRT plus WBRT (FSRT + WBRT group) with 35 patients treated by WBRT alone (WBRT group) on the effecting rate and survival rate. Results The completeness response rate was 49 % and 26 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. The effecting rate was 80 % and 71 % (P 0.05) in FSRT + WBRT and WBRT groups, respectively. The middle survival time was (11.0 ± 1.5) months and (6.5 ± 0.5) months (P < 0.05) in FSRT + WBRT and WBRT groups, respeetivley. The 0.5-, 1.0- and 1.5-years survival rate was 63 % and 41 % (P 0.05), 51 % and 23 % (P 0.05) and 24 % and 9 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. Conclusions The method with FSRT plus WBRT in the treatment of brain metastases tumor is safe and relieved focal symptom of patients quickly with lesser injury on normal tissue and the survival time be prolonged, it has better therapeutic effects than WBRT alone for treating brain metastases tumor.     

立体定向分次放疗联合全脑放射治疗脑转移瘤疗效分析

Objective To evaluate efficiency of brain metastases tumor using X-knife under farctionational stereotactie radiotherapy (FSRT) combine with whole brain radiotherapy (WBRT). Methods Retrospective comparing 51 patients treated by FSRT plus WBRT (FSRT + WBRT group) with 35 patients treated by WBRT alone (WBRT group) on the effecting rate and survival rate. Results The completeness response rate was 49 % and 26 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. The effecting rate was 80 % and 71 % (P 0.05) in FSRT + WBRT and WBRT groups, respectively. The middle survival time was (11.0 ± 1.5) months and (6.5 ± 0.5) months (P < 0.05) in FSRT + WBRT and WBRT groups, respeetivley. The 0.5-, 1.0- and 1.5-years survival rate was 63 % and 41 % (P 0.05), 51 % and 23 % (P 0.05) and 24 % and 9 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. Conclusions The method with FSRT plus WBRT in the treatment of brain metastases tumor is safe and relieved focal symptom of patients quickly with lesser injury on normal tissue and the survival time be prolonged, it has better therapeutic effects than WBRT alone for treating brain metastases tumor.     

乳腺癌骨转移临床相关因素的研究

Objective To study the clinical and imaging features of patients with bone metastases from breast cancer and identify the factors related to the incidence of bone metastases. Methods Three hundred and thirty-four patients with breast cancer were recruited into this study. Whole-body 99Tcm-methylene disphosphonate (MDP) bone scan, clinical staging, pathological, immunohistochemical and serological test results were analyzed retrospectively. χ2 test was used for statistical analysis. Results The incidence rate of bone metastases for patients with and without lymph node metastases was 71% (152/214) and 22. 5% (27/120), respectively (χ2 =72.80, P =0.000). The incidence rate of bone metastases from infiltrated non-specified and specified breast cancer was 69% (203/294) and 41.7% (5/12), respectively (χ2 =3. 97, P=0.046). Alkaline phosphatase (ALP) was elevated in 28.5% (51/179) and 14.9%(11/74) of patients with and without bone metastases, respectively (χ2 = 5. 25, P = 0.022 ). Carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 15-3, CA125, CA19-9 increased in 68.7% ( 123/179) and 27.0% (20/74) of patients with and without bone metastases, respectively (χ2 = 37. 03, P =0. 000). Conclusions The incidence of bone metastases from breast cancer is correlated to pathological types of primary tumor and lymph node metastases. Bone metastases occurs more frequently in patients with infiltrated, non-specified, primary cancer and with lymph node metastases. Serum ALP, CEA, CA15-3,CA125, CA19-9 might be the tumor makers for early diagnosis of bone metastases from breast cancer.     

Radionuclide brain perfusion studies in suspected brain death

The radionuclide brain perfusion study (RPS) has been suggested as a method of confirming suspected brain death. The hospital records and RPSs of 34 patients referred were reviewed because brain death was suspected. In every case but one the RPS showed absent or drastically reduced cerebral blood flow. No patient survived more than five days, and 25 survived less than 24 hours. These findings are consistent with the results of previous reports of a total of 248 patients; only one of 248 survived and was discharged from the hospital after having had a positive RPS. The RPS is highly accurate in confirming brain death.     

弥漫性脑损伤后脑缺血的实验研究

目的　运用大鼠弥漫性脑损伤 (DBI)模型研究脑外伤后脑缺血缺氧的形态学改变。　方法　采用Marmarou的DBI模型 ,光镜下观察微血管改变并测量顶叶皮质内微血管的截面积及微血管周的水肿面积 ;电镜下观察血脑屏障结构的形态学改变并半定量测定毛细血管周围的水肿范围。　结果　光镜下可见外伤后 2 ,6 ,2 4h微血管管径变窄 ,平均微血管截面积分别为 (41.77± 2 7.37) μm2 、(45 .0 9± 2 4 .75 ) μm2 、(49.38± 2 5 .13) μm2 ,均小于对照组 [(6 2 .0 7± 2 8.4 5 ) μm2 ](P <0 .0 5 )。伤后 6 ,2 4h微血管周围存在明显水肿。电镜下 2 ,6 ,2 4h血脑屏障结构有明显损害 ;微血管有痉挛、受压变窄及淤血三种改变。　结论　弥漫性脑损伤后存在明显的脑缺血缺氧的病理形态学改变。     

放射性脑损伤和脑肿瘤复发的鉴别诊断

放射性脑损伤是放射治疗的严重的并发症,其与脑肿瘤复发的鉴别诊断非常困难,目前主要依靠影像学诊断,核磁共振弥散加权像、磁共振波谱、正电子发射型计算机体层显像、单光子发射计算机体层显像等被认为对于鉴别诊断有一定的帮助,但其敏感性和特异性还有待于进一步研究。最终确诊依赖标本的组织学检查。     

轻度脑外伤患者SPECT局部脑血流显像

目的 探讨SPECT脑血流灌注显像在研究轻度脑外伤后临床症状发病机理中的作用。方法对39例无意识丧失、CT检查正常的轻度脑外伤患者进行^99Tc^m-双半胱乙酯(ECD)脑血流灌注断层显像。以双侧小脑平均每像素的均数为参比值，计算各大脑感兴趣区(ROI)放射性计数比值(RAR)。大脑皮质或基底神经节RAR低于70％，颞叶中部低于50％视为异常。结果39例患者中23例(59％)SPECT显示异常，其中3例为弥漫性血流灌注减低，20例为局部血流灌注减低灶，共计74个病灶。伤后3个月内脑血流灌注异常15例，2例为弥漫性血流灌注减低，13例为局灶性血流灌注减低；13例中发现病灶58个。8例受伤3个月后显像异常者，1例为弥漫性血流灌注减低，7例为局灶性血流灌注减低，发现病灶16个。结论 轻度脑外伤后患者主要症状为头痛、头昏、记忆力减退；无意识丧失的脑外伤患者可出现局部脑血流灌注减低，且SPECT检查比CT灵敏。     

99mTc HM-PAO brain perfusion SPECT in brain death

Diagnosis of brain death must be certain to allow discontinuation of artificial ventilation and organ transplantation. Brain death is present when all functions of the brain stem have irreversibly ceased. Clinical and electrophysiological criteria may be misinterpreted due to drug intoxication, hypothermia or technical artefacts. Thus, if clinical assessment is suboptimal, reliable early confirmatory tests may be required for demonstrating absence of intracranial blood flow. We have easily carried out and interpreted^99mTc HM-PAO SPECT in a consecutive series of 40 comatose patients with brain damage, without discontinuing therapy. Brain death was diagnosed in 7 patients, by recognising absence of brain perfusion, as shown by no intracranial radionuclide uptake. In patients in whom perfusion was seen on brain scans, HM-PAO SPECT improved assessment of the extent of injury, which in general was larger than suggested by CT.     

Treatment options in high-grade brain tumors: brain brachytherapy.

The extremely poor prognosis of high-grade brain tumors (glioblastoma multiforme and anaplastic astrocytomas) has been well documented in the literature. Almost 90% of patients die within 18 months after therapy, most commonly because of local persistence of the tumor, which may be controlled if a sufficient amount of irradiation can be delivered. Currently, postoperative radiation therapy offers the best median survival rate. However, the response to external-beam radiation therapy has reached a plateau because of the intolerance of healthy brain tissue to excessive irradiation. To treat these tumors, brachytherapy (interstitial implantation of radioactive sources) can be used with debulking surgery. This therapy is becoming an effective alternative to conventional external-beam radiation therapy, since it allows a higher dose to be delivered to the tumor bed without damaging the surrounding healthy brain tissue. With continual refinements of the technique, brachytherapy, performed by a skilled brachytherapy team, offers an opportunity to improve patient survival.     

大鼠二次脑损伤模型的建立

目的　建立弥漫性脑损伤 (diffusebrianinjury ,DBI)合并缺血性二次脑损伤 (secondarybrianinsult ,SBI)大鼠模型。　方法　在Marmarou模型基础上结扎双侧颈总动脉 30min ,制成缺血性SBI模型 ,观察大鼠神经损伤严重程度评分 (NSS)、脑组织含水量及室上区皮层损伤神经元数改变。　结果　合并SBI组大鼠死亡率 ( 4 8.1 % )约为单纯DBI组 ( 2 6 .2 % )的 2倍 (P <0 .0 5) ;合并SBI组在损伤 2 4h后NSS明显高于单纯DBI组 (P <0 .0 5) ;单纯DBI 1h后脑含水量明显升高 ,于 2 4h达高峰 ,随后逐渐下降 ,1 6 8h降至正常 ,而合并SBI后除 1h组外 ,其余时间组脑含水量均明显高于同时间单纯DBI组 (P <0 .0 5) ,且峰值提前至 1 2h ,1 6 8h仍未恢复正常 ;单纯DBI 6h后皮层神经元明显损伤 (P <0 .0 5) ,1 2h达高峰 ,1 6 8h恢复正常 ,而合并SBI组神经元损伤数 1 2h后还增加 ,2 4h达高峰 ,1 6 8h仍未恢复正常 (P <0 .0 5)。　结论　此模型可以复制SBI的重要临床特征 ,对SBI的基础研究有重要价值。     

Extra-axial brain tumors

Meningiomas, schwannomas, metastases, maldevelopmental cysts, epidermoids, dermoids and bone tumors represent the vast majority of extra-axial brain tumors. The location of extra-axial brain tumors affects treatment planning and predicts their prognosis. Computed tomography and particularly magnetic resonance imaging are used for diagnosis and localization. In this article, the imaging findings of the extra-axial brain tumors are discussed.

---

This revised version was published online in March 2005 with corrections to the author's name.